Save 20% on your next Cambridge Bioethics and Law online purchase
Page URL:

Study uncovers limitations of US breast cancer genetic testing

23 March 2006
By BioNews
Appeared in BioNews 351

Commercial genetic testing offered to women with a family history of breast cancer may provide false reassurance in some cases, a new US study shows. Researchers based at the University of Washington in Seattle studied women affected by hereditary breast cancer, who had all received negative results following BRCA1 and BRCA2 genetic testing. However, 12 per cent of these women had unusual BRCA gene mutations that commercial tests are not designed to detect. In a further six per cent of patients, the team identified mutations in other genes known to increase the risk of breast cancer. The scientists, who published their findings in the Journal of the American Medical Association (JAMA), suggest that more effective tests should be developed for such women.

Most cases of breast cancer are not inherited, but around 5-10 per cent are due to a gene mutation - often, but not always, in one of two 'BRCA' genes. Whilst most women have a 13 per cent chance of developing the disease in their lifetime, those with BRCA1 or BRCA2 mutations can face up to an 80-85 per cent chance. They also have an increased risk of ovarian cancer. In the past few years, researchers have identified other genes which, when mutated, can increase the risk of breast cancer. For example, in 2004, an international team confirmed that having a CHEK gene mutation doubles a woman's lifetime risk of the illness to 25 per cent. In the latest study, the scientists looked for mutations in the BRCA1, BRCA2 and CHEK genes, as well as the TP53 and PTEN genes - also linked to breast cancer.

The team studied 300 women with a family history of breast cancer who had developed the disease. They found that 35 of these women had received 'false negative' BRCA gene test results because they had unusual mutations, such as large chunks of the gene missing or rearranged. While the commercial test can detect small-scale BRCA gene mutations, it misses larger mutations, since these can only be detected using different methods - such as a technique called 'multiplex ligation-dependent probe amplification (MLPA). A further 14 patients (five per cent) had CHEK gene mutations, while three (one per cent) had inherited mutations in the TP53 gene. None of the women had a PTEN gene mutation.

Women with a high genetic risk of breast cancer can be offered increased screening, or sometimes preventative surgery to cut their chances of developing the disease. However, the JAMA study highlights the limitations of the tests currently used to identify such women in the US. The authors write that 'the clinical dilemma is what to offer to women with a high probability of carrying a mutation in BRCA1 or BRCA2 but with negative commercial test results'. The Utah-based company Myriad Genetics holds an exclusive BRCA gene testing licence in the US, unlike in Europe, where alternative testing kits capable of detecting unusual BRCA gene mutations are available.

Study leader Mary-Claire King told New Scientist magazine that the development of new tests is being stifled by inappropriate patent rules in the US, saying ' we need a competitive marketplace'. In reply, Bill Hockett of Myriad said that the company plans to introduce a more comprehensive BRCA genetic test kit later in 2006, which will use an approach similar to MLPA.

Testing misses some breast cancer mutations
Reuters |  22 March 2006
US commercial genetic testing does not detect all cancer-associated mutations in certain genes
EurekaAlert |  21 March 2006
US tests may miss 'breast cancer genes'
New Scientist |  22 March 2006
15 September 2014 - by Dr Rachel Montgomery 
A leading scientist involved in the identification of the BRCA1 gene mutation has recommended that genetic screening of the BRCA genes should be routinely offered to all women aged 30 years or over....
22 May 2009 - by Heidi Colleran 
A major lawsuit in the US is challenging the right of private companies to hold patents on genes involved in diseases, as well as their right to offer exclusive genetic tests. The American Civil Liberties Union (ALCU), the Public Patent Foundation (PPF), more than a dozen universities...
27 April 2009 - by Ben Jones 
The UK's Nuffield Council on Bioethics, an independent group of experts, is launching a new inquiry into the growing - and largely unregulated - provision of medical services through the internet and by consumer-targeted businesses. The multi-disciplinary group of experts will look at patients' experience of services including DNA...
30 June 2008 - by Dr Rebecca Robey 
A new, simple genetic test could improve the way breast cancer screening is approached in the UK, according to leading Cancer Research UK scientists. In a report published in the New England Journal of Medicine, the Cambridge University-based research team identified seven new gene variants that are...
24 September 2007 - by Ailsa Stevens 
On 10 September the US genetic testing company 'Myriad Genetics' launched an advertising campaign aimed at prompting women who have a family history of breast and/or ovarian cancer to discuss genetic testing options with their doctor. The company owns exclusive rights to the sale of a...
16 December 2005 - by BioNews 
Some UK women with a family history of hereditary breast cancer are waiting up to two years for the results of genetic tests, a new survey by CancerBACUP reveals. The charity found that in two of the 19 regional genetics centres that responded to the survey, women face a nine...
6 October 2005 - by BioNews 
Up to a third of all cases of breast cancer could have a genetic basis, a leading UK scientist said last week. Speaking at the annual conference of the National Cancer Research Institute, Professor Bruce Ponder said that research suggests there could be hundreds of variations in dozens of genes...
30 June 2005 - by BioNews 
The latest challenge to a patent held by US firm Myriad Genetics on a test for hereditary breast cancer has failed. The European patent Office (EPO) ruled on 29 June that European patent EP 785216, which relates to the BRCA2 gene, is to be maintained in its amended form. The...
21 May 2004 - by BioNews 
A large international study confirms that women who inherit a particular gene alteration have an increased risk of developing breast cancer. The CHEK2 gene mutation appears to double a woman's lifetime risk of the illness, from around 12 to 25 per cent. The researchers, who published their findings in the...
27 November 2003 - by BioNews 
UK and Canadian scientists have identified a new gene involved in breast and ovarian cancer, which they say provides a link between the inherited and non-inherited (sporadic) forms of the diseases. The gene, dubbed EMSY, appears to trigger sporadic breast cancer by shutting down the BRCA2 gene, which is one...
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.